NGS: MET mutations detected in 221/38,028 specimens, 3% of which (131) were lung adenocarcinomas; MDM2 and CDK4 amplification often occurred with MET exon 14 splicing mutations but not with MET amplification; Patients with MET exon 14 alterations, includingc.2888-5_2944del62, c.3028G>C, and c.3028+1G>T, showed partial responses to MET inhibitors. This evidence concerns the gene MET and lung adenocarcinoma.